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A B S T R A C T
Synthetic osteoinductive materials that mimic the human osteogenic niche have emerged as ideal candidates to
address this area of unmet clinical need. In this study, we evaluated the osteoinductive potential in a rabbit
orthotopic model of a magnesium-doped hydroxyapatite/type I collagen (MHA/Coll) composite. The composite
was fabricated to exhibit a highly ﬁbrous structure of carbonated MHA with 70% (2.1) porosity and a Ca/P ratio
of 1.5 (0.03) as well as a diverse range of elasticity separated to two distinct stiffness peaks of low (2.35  1.16
MPa) and higher (9.52  2.10 MPa) Young's Modulus. Data suggested that these speciﬁc compositional and
nanomechanical material properties induced the deposition of de novo mineral phase, while modulating the
expression of early and late osteogenic marker genes, in a 3D in vitro model using human bone marrow-derived
mesenchymal stem cells (hBM-MSCs). When tested in the rabbit orthotopic model, MHA/Col1 scaffold induction
of new trabecular bone mass was observed by DynaCT scan, only 2 weeks after implantation. Bone histo-
morphometry at 6 weeks revealed a signiﬁcant amount of de novo bone matrix formation. qPCR demonstrated
MHA/Coll scaffold full cellularization in vivo and the expression of both osteogenesis-associated genes (Spp1,
Sparc, Col1a1, Runx2, Dlx5) as well as hematopoietic (Vcam1, Cd38, Sele, Kdr) and bone marrow stromal cell
marker genes (Vim, Itgb1, Alcam). Altogether, these data provide evidence of the solid osteoinductive potential of
MHA/Coll and its suitability for multiple approaches of bone regeneration.
1. Introduction
A variety of medical conditions (e.g. traumas, diseases, deformities,
tumor resection) may require bone augmentation and reconstruction
strategies [1]. Autograft (i.e. patient's iliac crest-derived bone), allograft
(i.e. cadaveric bone), and demineralized allograft (or demineralized bone
matrix, DBM) are the most common bone-graft substitutes used in or-
thopedic surgery [2–5]. These types of grafts have limitations such as
pain (i.e. autograft), limited supply, or a potential allogenic response (i.e.
allograft) [6]. Administration of exogenous growth factors eliciting the
differentiation of progenitor cells to enhance bone regeneration has
emerged as a valid alternative approach [7]. Since its FDA approval in
2002, the use of recombinant human bone morphogenetic protein-2
adsorbed on a collagen sponge (INFUSE™) has been used as a bone
graft substitute to improve clinical outcomes [8–10]. However, severe
side-effects were linked to the superphysiological dosing of the growth
factor [11], and its use in clinical practice remains highly controversial
[12,13]. Stem cell–mediated bone repair has also been tested in various
clinical settings of bone reconstruction [14]. However, the higher level of
complexity and cost associated with cell-based bone regeneration ther-
apies have limited its widespread use in orthopedic surgery [15].
Many research groups have focused on developing controlled delivery
systems to decrease BMP-2 doses and limit its side-effects or to deliver
patient's cells more efﬁciently, however, engineering an osteogenic
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growth factor–free and cell-free synthetic scaffold for bone regeneration
remains highly desirable [16,17].
Growth factor–free and cell-free composite scaffolds fabricated from
hydroxyapatite, tricalcium phosphate ceramics, and polymer binders
(e.g. PLA, PLGA) have been proposed with mixed outcomes [5,18–21].
None of the current scaffolds have been applied clinically with fully
satisfactory performance and safety, compared with Infuse™ [22].
Among composite materials for bone regeneration, biohybrid com-
posite fabricated through bioinspired mineralization processes revealed
to be highly successful in a few pioneer clinical studies in Europe
[23–26]. During the synthesis of such composites—just like in the
bone—an organic template (i.e. collagen type I) drives the nucleation of
the mineral phase (i.e. hydroxyapatite), which is directly deposited
within the organic matrix [27], resulting in a composite material that
more closely resembles bone [28]. These biohybrid composites proved
highly successful in a few pioneer clinical studies of posterolateral spinal
fusion and osteochondral repair [23–26,29,30].
Toward this end, we recently optimized a biohybrid composite scaf-
fold consisting of magnesium-doped hydroxyapatite/type I collagen
(MHA/Coll), synthesized through a biologically inspired approach,
which recapitulates bone biomineralization [28]. In the present study,
we aimed at evaluating the osteoconductive potential of MHA/Coll in a
rabbit orthotopic model of non–load-bearing bone augmentation.
Although we previously demonstrated the osteogenic potential of this
material in a subcutaneous ectopic site [28], in the present study, we
investigated whether MHA/Coll could also induce bone formation in a
larger orthotopic model, without any heterologous growth factors or
cells. A biomimetic 3D in vitro cell culture system was used to investigate
the osteogenic differentiation of human bone marrow–derived mesen-
chymal stem cells (hBM-MSCs) induced by MHA/Coll. Its ability to
sequentially orchestrate the expression of crucial ostegenesis-associated
genes and overall harmonize the in vitro osteogenic differentiation of
hBM-MSCs was assessed by qPCR. In vivo, we investigated the ability of
MHA/Coll to fully recapitulate a regenerative bone niche, to not only
induce bone formation but also by assessing the presence of cells
expressing hematopoiesis-associated marker genes within the core of the
scaffold, like in mature bone.
2. Materials and methods
2.1. Fabrication of MHA/Coll
The scaffold was synthesized as previously described [28]. Brieﬂy,
bovine type I collagen (Nitta Casings Inc.) was dissolved at a concen-
tration of 10 mg/mL in acetate buffer at pH 3.5. H3PO4 was added to 100
g of the acetic collagen dough (40 mM), homogenized with a mechanical
blender, and then dropped in a solution of Ca(OH)2 (40 mM) and
MgCl2⋅6H2O (2 mM) in deionized (DI) water. The material underwent a
wet crosslinking in an aqueous solution of 1,4-butanediol diglycidyl ether
(2.5 mM), at 4 C. After crosslinking, MHA/Coll was washed three times
with DI water. The resulting slurry was molded in 48-well plates at a
thickness of 2 mm, to fabricate the scaffold for the in vitro studies,
whereas, for the in vivo studies, a cylindrical mold (4 cm  1 cm) was
used. The ﬁnal interconnected porosity of the scaffold was generated by
freeze drying. Brieﬂy, the materials were frozen from þ20 C to 20 C
in 3 h and then heated from 20 C to þ20 C in 5 h under vacuum
conditions (20 mTorr). Non-mineralized collagen scaffolds (Coll) were
also synthesized as previously described [28], as controls. All chemicals
were purchased from Sigma Aldrich.
2.2. Characterization of MHA/Coll through scanning electron microscopy-
energy-dispersive X-ray spectroscopy (EDS)
The morphology of MHA/Coll was assessed by a FEI Quanta 400
scanning electron microscopy (SEM), coupled with an energy-dispersive
X-ray spectroscopy (EDX) detector (analyzing program: EDAX Genesis)
(n ¼ 3).
Scaffolds were sputter coated with 10 nm of Pt/Pd, via a Plasma
Sciences CrC-150 Sputtering System (Torr International, Inc), and
imaged at a voltage of 10 kV.
2.3. Fourier-transformed infrared spectroscopy
Fourier-transformed infrared spectroscopy (FTIR) was performed
using a Nicolet 4700 Spectrometer (n ¼ 3). KBr pellets of 10 mm in
diameter were prepared bymixing 2 mg of grounded sample with 100mg
of KBr. Sixty-four runs were performed per sample. Spectra were
analyzed by the software EZ OMNIC (Nicolet) after baseline correction.
2.4. Thermal gravimetric analysis
The amount of mineral phase nucleated on the organic template (type
I collagen) was quantiﬁed by thermal gravimetric analysis (TGA). The
samples (n ¼ 3) were placed in alumina pans and subjected to a heating
ramp from 25 C to 800 C, at 10 C/min. A Q-600 TGA was used (TA
Instruments).
2.5. Scaffold porosity
The volumes of the scaffolds (cylinders of 6 mm cm x 6 cm) (Vs) were
calculated from their geometry. The porosity of the scaffolds was calcu-
lated as described elsewhere, through an ethanol adsorption method
[31]. Values are expressed as means  standard deviation (n ¼ 3).
2.6. Nanomechanical testing
The elastic properties of MHA/Coll were evaluated with atomic force
microscopy (AFM) by extracting the Young's modulus from AFM-acquired
force curves; a BioScope Catalyst AFM (Bruker Instruments) was used, in
tandem with MLCT-E silicon nitride cantilevers, with spring constant and
deﬂection sensitivity experimentally determined before each measure-
ment. For each scaffold (n¼ 3), 18 different 4-μm2 areas were considered,
with 100 equally spaced force curves obtained on each area. The contact
regime of the approach part of each force curve was ﬁtted with the
equation of a spherical indenter (Hertz model, Eq. (1)), using the ﬁtting
module of Nanoscope Analysis software, v1.50, and the elastic module
(Young's module) in each force curve was extracted according to Eq. (1):
F ¼ 4E
ﬃﬃﬃ
R
p
δ3=2
3ð1 υ2Þ (1)
In Eq. (1), F is the force applied by the cantilever tip to the scaffold (5
nN), E is the Young's modulus (ﬁt parameter), υ is the Poissons ratio
(0.5), and R the radius of the indenter of the cantilever tip (20 nm). Only
force curves with a goodness of ﬁt to Eq. (1) between 0.85 and 1 were
considered. Data distribution and statistical analysis were performed
using Wolfram Mathematica 9.0 and Minitab, v.14.1.
2.7. 3D culture of hBM-MSC on MHA/Coll
The hBM-MSCs used in the present study were isolated from the bone
marrow of two women (aged 28 and 35, respectively), at the Texas A&M
Institute for Regenerative Medicine (Temple, TX, USA). 104 cells/cm2
were seeded and incubated at 37 C in humidiﬁed atmosphere (90%)
with 5% CO2 and 5% O2.
The medium utilized was composed of α-minimum essential media
(MEM), 10% fetal bovine serum (FBS), 2% glutamine, 1% β-ﬁbroblast
growth factors (FGF), and 1% streptomycin/amphotericin B (Gibco).
Cells were serially passaged using TrypLE Express (Invitrogen) when at
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80% conﬂuency. At passage 4, 3⋅105 hBM-MSCs were seeded on MHA/
Coll. Cells were also cultured on collagen scaffolds (Coll) (n ¼ 8) with
regular media (negative controls) or osteogenic media (positive control
for osteogenic differentiation) (n ¼ 8). The osteogenic medium was
purchased from Gibco and used according to the protocols of the man-
ufacturers. Medium change was performed every three days.
2.8. Imaging of the 3D cultures
At 3 weeks, the 3D cultures (n ¼ 3) were imaged by a A1 confocal
laser microscope (Nikon) and SEM. Cell distribution was assessed by
confocal laser microscopy; the cells were ﬁxed with 4% para-
formaldehyde (R&D Systems) and then stained with DRAQ5™ (Thermo
Fisher), as per manufacturer's protocol. The scaffolds were visualized in
the 40,6-diamidino-2-phenylindole (DAPI) ﬁeld (350 nm), where they are
intrinsically autoﬂuorescent. Images were analyzed with the software
NIS Elements (Nikon).
The morphology of the cells was evaluated by SEM. For SEM imaging;
cells were ﬁxed with 2.5% glutaraldehyde (Electron Microscopy Science)
and then dehydrated in increasing concentrations of ethanol, up to 100%,
then vacuum dried [32]. Before imaging, the samples were sputter coated
with 9 nm of Pt/Pb, and imaged at 10 kV. The amount of de novo calcium
phosphate phase produced by the hBM-MSCs was quantiﬁed by EDS
analysis. The overall amount of Ca, Mg, and P was quantiﬁed at 3 weeks
of culture.
Data were normalized to the amount of Ca, Mg, and P found in both
cell-free Coll and MHA/Coll scaffolds (n ¼ 3).
2.9. Gene expression analysis
The gene expression of selected osteogenic marker genes and of the
magnesium transporter 1 (MAGT1) and transient receptor potential
cation channel subfamily M member (7TRPM7) (listed in Table S1 of the
Supplementary Information) was assessed by q-PCR, for hBM-MSCs
cultured in vitro on MHA/Coll or Coll (CTRL), after 1 and 3 weeks of
culture, as described in paragraph 2.7.
The MHA/Coll specimens harvested from the rabbits at 6 weeks were
designated to quantitative - polymerase chain reaction (q-PCR) analysis
(n ¼ 8) and compared with specimens of native rabbit transverse process
bone, used as control. Both scaffolds and tissue specimens were
embedded in 1 mL of Trizol reagent (Life Technologies), homogenized
and the RNA extracted with a RNeasy column (Qiagen), as per the
manufacturer's protocol. RNA concentration and purity were measured
using a NanoDrop ND1000 spectrophotometer (NanoDrop Technolo-
gies). The cDNA was synthesized from 1000 ng of total of RNA, using the
iScript retrotranscription kit (Bio-Rad Laboratories). Transcribed prod-
ucts were analyzed using Taqman fast advanced master mix (Thermo-
Fisher Scientiﬁc) and the appropriate target probes (Supplementary
Table S1, ThermoFisher Scientiﬁc) on a StepOne Plus real-time PCR
system (Applied Biosystems).
2.10. Rabbit bone orthotopic model
To assess MHA/Coll integration and follow bone regeneration, MHA/
Coll was implanted unilaterally in rabbit, and bone formation was eval-
uated at 6 weeks, as previously described [33], through a modiﬁed spinal
fusion procedure described elsewhere [34,35]. All animal work was
approved and supervised by the Houston Methodist Research Institute
(HMRI) Institutional Animal Care and Use Committee (IACUC,
AUP-0115-002) and guidelines from the American Association for Lab-
oratory Animal Science as well as animal care procedures outlined by the
National Institute of Health (NIH) Guide for the Care and Use of Labo-
ratory Animals and were strictly enforced. Scaffolds (4 cm  1 cm) were
sterilized in an AN74ix ethylene oxide chamber (Andersen, Haw River,
North Carolina). New Zealand white rabbits (n ¼ 12, Charles River Labs,
Houston, Texas) weighing 4.0–5.0 kg each underwent a 72-h acclimation
period upon arrival before being housed individually in cages and
allowed weight-bearing ambulation, food/water ad libitum, and a
tasteless aqueous antibiotic solution (penicillin) for infection prophy-
laxis. Under the effects of ketamine, midazolam, and inhaled isoﬂurane
anesthesia, a dorsal midline incision approximately 10 cm in length was
made directly over palpable spinous processes of the lumbar spine
through the skin and subcutaneous tissues. Next, bilateral 6-cm incisions
were made just lateral to the palpable mammary bodies from the level of
the L4 vertebra to the L7 vertebra. Using blunt dissection between the
longissimus, multiﬁdus, and ileocostalis muscles, the transverse pro-
cesses (TPs) of L5-L6 were exposed and cleaned of thin muscular at-
tachments using a molt-style periosteal elevator. Extra care was taken
during dissection near the superior edge of the TP–vertebral body (VB)
junction, where the neurovascular bundle exits the spinal canal. Each TP
and adjoining intertransverse VB portion was decorticated using a
high-speed cone burr until punctate bleeding from the marrow space was
encountered. A 1 3 cmMHA/Coll was placed between the decorticated
TPs on the experimental anatomical right side, functioning in effect to
bridge the defect; meanwhile, the anatomical left side was used as an
internal control, receiving decortication alone. Incisions were approxi-
mated with suture, and after 6 weeks in vivo, animal subjects were
euthanized by carbon dioxide inhalation, for harvest of the biomaterial
samples. No animals suffered any unforeseen morbidity or mortality
requiring removal from the study.
2.11. DynaCT scan and measurements of trabecular and cortical bone
mass
Under the effect of sedation, lumbosacral computed tomography
(DynaCT) scans were acquired for all animals (n¼ 12) at 24 h, 2, 4, and 6
weeks after implantation, with an Axiom Artis C-arm (d)FC (Siemens
Healthcare). Scanning was performed with a 48 cm  36 cm ﬂat-panel
integrated detector. Acquisition parameters for DynaCT were as fol-
lows: 70 kV tube voltage, automatic tube current of 107 mA, 20 s scan.
Each scan entailed 222 of rotation, with 1 image taken every 0.5 for a
total of 444 images (each digital acquisition had a matrix of 514  514
pixels) per acquisition. Three-dimensional rendering was obtained
through the Inveon Research Workplace 4.2 Software (Siemen Medical
Solution Inc.). All DynaCT imaging ﬁles were processed and analyzed
using Siemens’ Inveon Research Workplace. Two regions of interest
(ROIs) of identical dimensions were created. One on each surgical side,
these ROIs deﬁned the area of analysis to each side of our sample. Uti-
lizing the Hounsﬁeld unit values for tissue densities [36,37], we were
able to establish a range that helped us determine the bone volume
deﬁned by our ROI. The values used as the minimum threshold to
quantify trabecular and cortical bone were the following: for trabecular
bone (TB)-like tissue density, the value used was >200HU. For mea-
surement of cortical bone-like tissue density, the units value was
>500HU. The quantiﬁcations obtained in each study subject were
compared with the decorticated control side. De novo bone mass was
calculated as the difference between the quantiﬁcation at decorticated
and scaffold for bone density corresponding to 200HU and 500HU,
respectively.
2.12. Bone histomorphometry
The implant was isolated from the proximal and distal ends of the
spine using two axial cuts. The sample was then cut sagittally using the
spinal canal as our center point. Afterward, each half was dehydrated and
inﬁltrated and embedded with acrylic resin. Sections were created using
the cut and grind technique with the EXAKT Cutting and Grinding System
(5–10 μm sections at 500 μm between each level). Sections were stained
with Von Kossa/MacNeal's Tetrachrome, Goldner's Trichrome, and he-
matoxylin and eosin staining (n ¼ 4).
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2.13. Statistical analysis
All experiments were performed at least in triplicates (for the exact
number of replicates, see speciﬁc paragraphs). The statistical analysis
was performed through the software Prism GraphPad. A one-way anal-
ysis of variance (ANOVA) with a post-hoc unpaired t-test was used. Data
Fig. 1. (A) Representative TGA analysis of the mineral content of MHA/Coll and (B) Young's Modulus measurements. TGA, thermal gravimetric analysis; MHA/Coll,
magnesium-doped hydroxyapatite/type I collagen.
Fig. 2. Confocal laser microscopy and SEM images of hBM-MSCs (green) cultured on Coll, Coll in osteogenic media and MHA/Coll, at 3 weeks (A-C and D-F,
respectively). Relative amount (intensity) of magnesium, phosphate and calcium in the scaffolds, for the three corresponding experimental groups, quantiﬁed by EDS
analysis. Data are normalized to cell-free Coll and MHA/Coll scaffolds, as baselines. SEM, scanning electron microscopy; hBM-MSC, human bone marrow-derived
mesenchymal stem cell; MHA/Coll, magnesium-doped hydroxyapatite/type I collagen.
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are presented as mean  standard deviation. For all experiments, * was
used for p< 0.05, ** for p< 0.01, and *** for p< 0.001, and **** for p<
0.0001.
3. Results
3.1. Characterization of MHA/Coll
The structure of MHA/Coll was evaluated by SEM (Fig. S1). The high-
magniﬁcation SEM micrographs showed the highly ﬁbrous structure of
the composite (Fig. S1A), where the collagen ﬁbers resulted fully
mineralized with an amorphous mineral phase (Fig. S1B). The porosity of
MHA/Coll was assessed at 70% (2.1), compared with the 84% (9) of a
non-mineralized scaffold (Fig. S2).
Elemental analysis of MHA/Coll was performed using EDS, where a
Ca/P ratio of 1.5 (0.03) was observed (Fig. S1C). EDS mapping assessed
the homogenous distribution of all evaluated elements, within the
analyzed areas (Fig. S3). The interaction between MHA and the collagen
ﬁbers on which it was nucleated was assessed by FTIR spectroscopy
(Fig. S1D). In MHA/Coll, a shift from 1340 to 1337 cm1 in the band
corresponding to the stretching of -COO- group of collagen was observed,
because of its interaction with the positively charged MHA nanocrystals.
The peak at 872 cm1 in MHA/Coll reveals that the MHA nucleated on
the collagen was carbonated, as well as in the MHA powder (Fig. S4).
TGAwas performed to assess the extent of mineral phase nucleated on
type I collagen. An approximate 40% loss of MHA/Coll initial weight was
found, indicating an approximate 60% of actual mineral phase content
within the composite (Fig. 1A). AFM analysis was performed on MHA/
Coll, to evaluate its elastic properties (Fig. 1B). A total of 521 Young's
modulus values were considered, from a minimum of three scaffolds
which were prepared independently, demonstrating the robustness of the
fabrication technique. While the data set presented an overall Young's
modulus close to 6 MPa, a wide range of scaffold stiffness data was
observed, as shown in Fig. 1B, with two distinct peaks of Young's
Fig. 3. (A) Relative-fold expression of osteoprogenitor, preosteoblast, and early and late osteoblast marker genes at 1week and 3 weeks of in vitro culture of hBM-MSCs
cultured on MHA/Coll and control Coll scaffolds. Results were ﬁrst normalized to the expression of the housekeeping gene GAPDH and then expressed as “relative-fold
expression” in comparison to the expression level of the same gene from the CTRL (Coll). Values are reported as mean  standard deviation. A value of p < 0.05 was
considered statistically signiﬁcant: *p < 0.05, **p < 0.01, ***p < 0.001. (B) Schematic representing the different stages of osteogenic differentiation of mesenchymal
stem cells, with associated relevant marker genes. hBM-MSC, human bone marrow-derived mesenchymal stem cell; MHA/Coll, magnesium-doped hydroxyapatite/
type I collagen.
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Modulus, representing more elastic collagen areas and those that were
signiﬁcantly stiffer or less elastic. The ﬁrst distribution peak, comprising
all data points between 0.1 and 5MPa and including 70% of the total data
set, exhibited an elastic modulus of 2.35  1.16 MPa. These areas were
interspersed with stiffer areas of the second peak, which comprised 30%
of the total data set and exhibited a range between 5.5 and 14 MPa, with
an average Young's modulus of 9.52  2.10 MPa. The raw data are re-
ported in Table S2.
3.2. In vitro test of MHA/Coll with hBM-MSCs
After 3 weeks of culture, hBM-MSCs-MHA/Coll constructs were
imaged by confocal laser microscopy to assess their overall morphology
and cell distribution. Cells cultured on Coll in regular media, used as
controls, resulted organized along the walls of the scaffold pores, and the
scaffold itself was found highly porous (Fig. 2A).
Cells cultured on Coll in osteogenic media were found organized in
bigger clusters, within and along the pore walls (Fig. 2B). MHA/Coll
samples displayed a completely different morphology (Fig. 2C). The
scaffold appeared denser and less porous, with cells organized in big
clusters within the pores. These observations were further conﬁrmed by
the SEMmicrographs. Cells on Coll (regular media and osteogenic media)
were easily identiﬁed, along the pores of the scaffold (Fig. 2D and E),
whereas the cells on MHA/Coll appeared embedded within the amor-
phous mineral phase/collagen matrix of the scaffold and were hardly
identiﬁable (Fig. 2F). EDS analysis was also performed on these samples
to assess the deposition of mineral phase by the hBM-MSCs and its
eventual elemental composition (Fig. 2G, H, I). In all samples, some
extent of mineralization was found, but the most signiﬁcant amount of de
novo mineralization was found in the MHA/Coll experimental group.
3.3. In vitro osteogenic differentiation of hBM-MSCs
We identiﬁed a comprehensive panel of osteogenic marker genes and
monitored their dynamic expression at early and late differentiation
stages (1 week and 3 weeks, respectively) for hBM-MSCs cultured on
MHA/Coll and Coll scaffolds (used as controls). For cells cultured on
MHA/Coll, we observed a notable induction of osteoprogenitor marker
genes and early osteoblast (OB) marker genes at 1 week and a less pro-
nounced increase in their expression at 3 weeks; whereas late OB marker
genes and osteocyte marker genes resulted expressed at a higher level at
3 weeks (Fig. 3, and summary of data and their statistical signiﬁcance in
Table 1).
3.4. In vitro expression of MAGT1 gene by hBM-MSCs
Considering the presence of calcium and magnesium in the formu-
lation of our MHA/Coll, we investigated the in vitro expression of genes
MAGT1 and TRPM7. MAGT1 was found signiﬁcantly overexpressed at
both experimental time points of 1 week (p < 0.001) and 3 weeks (p <
0.05), when hBM-MSCs were cultured on MHA/Coll, compared with the
CTRL (Coll) (Fig. 4). MAGT1 was found expressed at a higher level at 1
week than 3 weeks. TRPM7 was found to be not overexpressed at neither
time points, compared with the CTRL (data not shown).
3.5. Orthotopic de novo bone formation
Operatively, MHA/Coll was found easy to handle. When explanted,
the implants were found signiﬁcantly hardened and bone-like in
appearance. Boney transformation of scaffolds was monitored by DynaCT
(Fig. 5A–C), at 2, 4 and 6 weeks, and ﬁnally evaluated by histology at 6
weeks (Fig. 6). Compared with the decorticated side alone, there was
signiﬁcant mineral deposition. While no difference in TB formation was
seen over time, the mean bone mass at 200HU decreased over time.
Conversely increases in the mass of bone measured at 500HU and asso-
ciated with cortical bone was seen at 4 weeks and 6 weeks comparedwith
the 2-week time point (Fig. 5D). Mean de novo bone formation increased
from week 2 (152.1  38.2 mm3) to week 4 (293.9  122.4 mm3) (p <
0.05). This signiﬁcant increase in the cortical fraction of newly formed
bone continued into week 6 (256.2 55.6 mm3). Fromweek 2 to week 4,
the cortical fraction of bone nearly doubled. Overall, more TB was
measured compared with cortical bone.
At 6 weeks, histology conﬁrmed the formation of an extended mass of
bone-like tissue within the implants. A signiﬁcant amount of mineral
phase was found in MHA/Coll samples evaluated through Von Kossa
stain, on non-decalciﬁed tissue slices. The staining resulted of similar
intensity to TB, used as control (Fig. 6A and B), and the osteoid portion of
the tissue was clearly distinguishable, although it appeared not fully
remodeled at this time point, compared with vertebral bone. Similarly,
Goldner's Trichrome staining of MHA/Coll samples allowed to clearly
discriminate between mineralized bone matrix (mineral phase—MP) and
osteoids, where OB and osteoclasts (OC) were both identiﬁed (Fig. 6C
and D). Finally, hematoxylin and eosin staining conﬁrmed the presence
of OCs and OBs in the osteoid area of MHA/Coll samples, similarly to the
control TB specimens (Fig. 6E and F).
3.6. In vivo osteogenesis
We assessed the stage of remodeling of the newly formed bone-like
Table 1
Relative-fold expression of osteoprogenitor, early and late osteoblast, and oste-
ocyte marker genes at 1 week and 3 weeks for hBM-MSCs cultured on MHA/Coll
and control Coll scaffolds.
Gene Relative-fold expression
1 week 3 weeks
Osteoprogenitor marker genes:
RUNX2 21.33  2.03 (p < 0.01) 0.95  0.12
SP7 125.35  12.42 (p < 0.01) 2.19  0.25 (p < 0.05)
STAT3 8.03  1.14 (p < 0.01) 0.64  0.03
Early osteoblast marker genes:
COL1A1 7.26  1.51 (p < 0.05) 4.93  0.58 (p < 0.01)
ALPL 14.11  1.85 (p < 0.01) 8.58  0.44 (p < 0.001)
Late osteoblast marker genes:
SPARC 4.81  0.50 (p < 0.01) 12.92  1.21 (p < 0.01)
BGLAP 3.69  0.45 (p < 0.01) 6.41  0.49 (p < 0.001)
Osteocyte marker genes:
SPP1 1.23  0.16 (p < 0.05) 23.41  2.30 (p < 0.01)
OPG 1.03  0.07 42.16  1.98 (p < 0.001)
hBM-MSC, human bone marrow-derived mesenchymal stem cell; MHA/Coll,
magnesium-doped hydroxyapatite/type I collagen.
Fig. 4. Relative-fold expression of MAGT1 at 1week and 3 weeks of in vitro
culture of hBM-MSCs cultured on MHA/Coll and Coll (CTRL). TRPM7 was not
found expressed at neither time points (data not shown). Results were ﬁrst
normalized to the expression of the housekeeping gene GAPDH and then
expressed as “relative-fold expression” in comparison to the expression level of
the same gene from the CTRL. Values are reported as mean  standard devia-
tion. A value of p < 0.05 was considered statistically signiﬁcant: *p < 0.05, **p
< 0.01. hBM-MSC, human bone marrow-derived mesenchymal stem cell; MHA/
Coll, magnesium-doped hydroxyapatite/type I collagen; MAGT1, magnesium
transporter 1.
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mass through q-PCR. Regarding the expression levels of the selected
osteogenesis-associated marker genes, DLX5 (BMP-responsive transcrip-
tional activator) was the only gene that was not overexpressed in the
newly formed bone-like mass within the scaffold, comparedwith TP bone
(not statistically signiﬁcant), whereas the expression level of the
remaining early and late osteogenesis-associated marker genes was
signiﬁcantly higher compared with the control (TP bone) (RUNX2 2.21
 0.24 (p < 0.05), COL1A1 2.28  0.16 (p < 0.05), SPARC 3.19  0.07
(p < 0.01), and SPP1 3.67  0.09 (p < 0.001)) (Fig. 7). The signiﬁcant
overexpression of SPARC and SPP1, which are markers for late OBs and
osteocytes, are evidence that bone maturation on the scaffold initiated at
only 6 wks.
The selected bone marrow stromal cell–associated marker genes were
expressed in the newly formed bone-like mass generated by MHA/Coll,
but their level of expressionwas lower compared towith the control. Only
VCAM1, which is usually downregulated during hematopoietic progen-
itor cell mobilization, was found overexpressed 1.95  0.25-fold
comparedwith TP bone, suggesting newly developed hematopoietic stem
cells (HSCs) had lowmigration activity at 6 weeks. CD38, SELE, and KDR,
which are key HSCs surface markers, were found expressed in the newly
Fig. 5. 3D rendering obtained by DynaCT scan of a representative spine showing radiologic bone mass formation in correspondence of the scaffold (arrowhead) (A, B).
Bone-like scaffold at 6 weeks, upon retrieval, showing integration with surrounding tissue (arrowhead) (C). MHA/Coll allowed early and robust trabecular bone
formation as well as cortical bone ingrowth as early as 2 weeks (D).
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formed bone mass within the scaffold, at levels slightly lower than that of
TP bone (0.54 0.15, 0.51 0.04 *p< 0.05 and 0.61 0.02 **p< 0.01,
respectively) (Fig. 6). Similarly, all selected bone marrow stromal cells
marker genes were found expressed, but at slightly lower levels than
those of the control (ALCAM: 0.39  0.02, ITGB1: 0.73  0.03, and VIM:
0.72  0.06), with an overall expression level of 39%, 73%, and 72%,
respectively, when compared with native bone.
4. Discussion
Regenerative bone tissue engineering encompasses a wide range of
different strategies, materials, and biologics aimed at regenerating bone
[38]. Owing to the varying types and functions of bone tissue, there is no
universal approach to bone tissue engineering; and scaffolds, for
example, are required to be tailored to speciﬁc design and mechanical
strength requirements, depending on location and microscale architec-
ture of speciﬁc bones [39]. Although the use of BMP-2 allowed for bone
regeneration in multiple clinical settings, the severe side-effects associ-
ated with high dosing discouraged many orthopedic surgeons from using
it. Thus, a fully biocompatible and biodegradable device, able to induce
bone formation without the use of recombinant growth factors or any
other exogenous biologics, would signiﬁcantly beneﬁt the current stan-
dard of care for bone regeneration [28]. In the present work, we inves-
tigated the osteogenic potential of a biomimetic hybrid
composite—MHA/Coll—demonstrating its ability to support the forma-
tion of newly formed bone-like tissue in a large orthotopic model, within
only 6 weeks from implantation, without the use of any exogenous
biologics.
Fig. 6. Von Kossa (A, B), Goldner's Trichrome (C, D), and hematossilin-eosin (E, F) staining of non-demineralized vertebral trabecular bone and MHA/Coll specimens
at 6 weeks, respectively. TB, trabecular bone; OS, osteoid; MP, mineral phase; OB, osteoblast; OC, osteoclast; BMSC, bone marrow stem cell.
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Regenerating bone is characterized by the presence of woven, or
immature bone, with Young's moduli that range from 30 to 1000 MPa
depending on the distance from the fracture point, with an average of
around 13 MPa [40]. Nanocrystalline apatites have been successfully
substituted with a variety of ions, to reach increasing degrees of bio-
mimicry to the composition of the bone mineral phase [41]. However,
devices fabricated with these biomimetic apatites lack in recapitulating
other vital features of bone, such as its architecture and mechanical
properties. Synthetic and natural polymers have been combined with
nanoapatites to create loosely packed ﬁbrous meshes that have a much
lower stiffness and facilitate cellularization and encourage new tissue
formation by progenitor and bone cells [42]. Our MHA/Coll scaffold was
synthesized through an innovative biologically inspired synthetic pro-
cess, which was demonstrated to recapitulate the main steps of bone
biomineralization [28]. Similarly to the biomineralization process of the
bone, the organic template on which the biomimetic apatite is nucleated
plays a crucial role. In fact, during the synthesis, type I collagen allows for
the structural and morphological control over the growth of the apatite
crystals, leading to a nanoscopic and microscopic architecture similar to
that found in human bone [28,43]. During the pH-driven self-assembly of
the organic template, the mineral phase is synthesized and nucleated
directly on the collagen ﬁbers. This resulted in a composite material
(Figs. S1A and B), with unique chemical, morphological, and mechanical
cues, known to be crucial in guiding cell recruitment and migration [28].
Previous nanostructural analysis of single-collagen bundles showed that
MHA was homogenously nucleated along the collagen bundles, overall
increasing their roughness when compared with unmineralized collagen
ﬁbers [28]. Herein, for the ﬁrst time, we have assessed the nano-
mechanics of these collagen ﬁbers in situ, within the gross 3D MHA/Coll
scaffold construct compared to bone, by nanoindentation or force volume
mapping. MHA/Coll demonstrated Young's modulus of less than 100
MPa and was not matched speciﬁcally to the stiffness of immature bone
(Fig. 1). It is well known that cells are able to sense and voluntarily
migrate along gradients of stiffness within a material (durotaxis) [44]. In
our study, hBM-MSCs underwent osteogenic differentiation when seeded
on MHA/Coll in vitro, and host's cells sequestered retain an osteogenic
genotype and phenotype in vivo, which may suggest that a softer highly
biomimetic material, where progenitor and somatic cells experience a
relatively low stiffness, could be more conducive for new tissue forma-
tion. Thus, the gradients of varying nanomechanical properties observed
may have contributed to enhanced cell ingrowth, providing a niche for
such osteogenic differentiation and subsequent repair. This is further
supported by the efﬁcient osteodifferentiation of hBM-MSCs and their de
novo mineral deposition characterized in vitro (Fig. 2), and of new bone
formation characterized in vivo by DynaCT scan and histology (Figs. 5
and 6 respectively).
We had previously found that hBM-MSCs upregulated OB-associated
marker genes when cultured on MHA/Coll, in vitro [28]. Interestingly, in
the present study, a more thorough osteogenesis-associated gene
expression analysis revealed that hBM-MSCs had sequentially upregu-
lated all the key marker genes of each stage of the osteogenic differen-
tiation and maturation pathway when cultured on MHA/Coll, without
any exogenous biologics and in a more efﬁcient fashion than when
cultured in osteogenic media (Fig. 3).
Other biomaterials containing magnesium have been proposed for
bone regeneration, as they allow for enhanced osteogenesis and
increased bone density [45,46], although the mechanisms underlying the
biological effects of magnesium are still mostly unveiled [47–51]. Among
all, magnesium-based bioceramic phases have been tested because of
their superior osteogenic properties, signiﬁcant bone-like apatite for-
mation ability, and excellent bioactivity [52–54]. Recent ﬁndings sug-
gested that the genes MAGT1 and TRPM7 (encoding for the
magnesium-selective cation transporter magnesium transporter 1 and
the non-magnesium–speciﬁc transient receptor potential cation channel
subfamily M member 7, respectively) are upregulated and signiﬁcantly
contribute to the orchestration of the osteogenic differentiation of
h-MSCs [55]. It was also demonstrated that silencing either one of them
hastens the expression of osteogenic markers as well as calcium deposi-
tion in vitro [55]. Thus, the overexpression of MAGT1, at as early as 1
week of culture on MHA/Coll compared with the control (Fig. 4), would
suggest that the composition of MHA/Coll (containing both magnesium
and calcium) itself may improve the orchestration of the osteogenic
Fig. 7. Releative-fold Expression of osteogenic (A), hematopoitic (B), and bone marrow–associated marker genes (C) detected for MHA/Coll group at 6 weeks after
implantation in the orthotopic model in rabbit, compared with naïve spinal bone. Results were ﬁrst normalized to the expression of the housekeeping gene GAPDH and
then expressed as “relative-fold expression” in comparison to the expression level of the same gene from the CTRL. Values are reported as mean  standard deviation.
A value of p < 0.05 was considered statistically signiﬁcant: *p < 0.05, **p < 0.01, ***p < 0.001. TP, transverse process; MHA/Coll, magnesium-doped hydroxy-
apatite/type I collagen.
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differentiation of hBM-MSCs, and even more efﬁciently than osteogenic
media. Moreover, similarly to our in vitro ﬁndings, Castiglioni et al.
observed that when TRPM7 is silenced and MAGT1 is upregulated, the
osteogenic differentiation of h-MSCs is enhanced and associated with
increased calcium deposition [55]. In our study, we found MAGT1 was
overexpressed at both 1 and 3 weeks, whereas TRPM7 was down-
regulated (Fig. 4). This could have enhanced the osteogenic stimulus
delivered by the scaffold, through a mechanism similar to that described
by Castiglioni et al., which could in part explain the promising results
obtained in vivo within only 6 weeks from implantation of MHA/Coll in
an orthotopic model.
With the highest level of expression of MAGT1 being at the earlier
time point in vitro (1 week), we hypothesize that this early MAGT1-
mediated harmonized osteogenic differentiation of the progenitor cells
could explain the signiﬁcant formation of new bone in vivo (Fig. 6). In
fact, in the orthotopic model, the scaffold promoted the formation of a
signiﬁcant amount of bone-like mass with density similar to that of TB
(>200HU) [37], only 2 weeks after implantation in the orthotopic model.
Furthermore, its maturation and densiﬁcation also initiated at only 2
weeks, as demonstrated by the increasing volume of newly formed bone
having density similar to that of cortical bone (>500HU) [37] that
accumulated over the weeks (Fig. 4). This represents a signiﬁcant
accomplishment considering it was achieved without the contribution of
any heterologous cytokines or engraftment of progenitor cells on the
scaffold, before implantation, and correlated with our previous ﬁndings
[28]. Because the rapid integration and remodeling of a bone scaffold is
vital for the ultimate outcome, these results are all the more signiﬁcant
and highlight the enhanced osteoinductive nature of MHA/Coll.
Finally, particularly remarkable of this study was not only the efﬁ-
cient recruitment of progenitor and bone cells in vivo (clearly identiﬁed
by histology and through gene expression, Figs. 5 and 6, respectively),
which surely facilitated the formation of bone-like tissue, but also that
some of such cells belonged to the hematopoietic lineage. When
comparedwithmature bone (naïve TP bone), the selected hematopoietic-
associated and bone marrow stromal cell–associated marker genes dis-
played a lower level of expression within our scaffold (Fig. 6). However,
these results are still very signiﬁcant as they reveal a developing primi-
tive hematopoietic niche within the newly formed tissue formed by
MHA/Coll. It was been recently reported that mesenchymal progenitors
are sufﬁcient to create bony ossicles that are populated by host vascu-
lature and hematopoietic stem cells [56,57]. Similarly, our data suggest
that MHA/Coll is able to be not only colonized by mesenchymal osteo-
progenitors but also by hematopoietic precursors that may contribute to
the assembly of a hematopoietic niche, toward a full maturation of the
newly deposited bone tissue [56]. Although evaluating the formation of
bone marrow was not the main purpose of this study, this data laid the
foundation for further investigation of the ability of MHA/Coll to pro-
mote the regeneration of functional bone tissue, including a bonemarrow
niche.
To our knowledge, this study reports for the ﬁrst time the formation of
an extensive mass of TB–like and cortical bone–like tissue within only 6
weeks after implantation, through a biologics-free scaffold, able to sup-
port the formation of both an osteogenic and hematopoietic niche.
5. Conclusions
In this study, we reported the enhanced osteoconductive potential of
MHA/Coll, a highly biomimetic hybrid composite, based on magnesium-
substituted hydroxyapatite and type I collagen, synthesized through a
bioinspired mineralization process of type I collagen. We ﬁrst demon-
strated its ability to induce, orchestrate, and harmonize the osteogenic
differentiation of hBM-MSCs in vitro. Second, the signiﬁcant new TB and
early cortical bone formation at 2 weeks and 4 weeks clearly proved the
osteoinductive nature of MHA/Coll. Finally, our ﬁndings suggested that
the remodeling we observed may involve also the formation of a bone
marrow-like niche, which could lead to functional bone tissue
regeneration, at longer time points.
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